When it comes to antihypertensive drugs, I believe the first thing that comes to mind is nifedipine, amlodipine, felodipine, etc. But compared to these antihypertensive drugs, Benidipine is a newer class of antihypertensive drugs, and it has its own characteristics in terms of its effects.
Different types of diphenhydramine have different action time, the earliest listed nifedipine, belongs to the short-acting antihypertensive drugs, the current common dosage form is made of sustained-controlled release preparation to play its long-acting antihypertensive effect, and after the listing of amlodipine, itself is the half-life of up to 17-35 hours of the drug, the ordinary tablets can be played to play a role of long-acting control of blood pressure, once a day can be taken.
Compared to amlodipine, benidipine is also an ordinary tablet can play a long-acting antihypertensive effect of the new diphenhydramine class of drugs, but benidipine's long-lasting, not through the half-life time is long to realize, benidipine's plasma half-life of only 0.9 ~ 1.7 hours, but this is going to go to a high degree of fat solubility, can be tightly bound with the vascular smooth muscle cell membranes, the rate of dissociation of slow, so as to play its long-acting antihypertensive effect. , thus exerting its long-lasting antihypertensive effect. This determines the Benidipine can be rapid effect, but also can be long-lasting control, is more advantageous antihypertensive drugs.
We all know that diphenhydramine antihypertensive drugs belong to the calcium channel antagonist class (CCB) drugs, by inhibiting the intracellular flow of calcium ions to play a role, but different CCB drugs, its antagonism of the type of calcium channel also varies, usually the cellular calcium channel has three kinds of, and other diphenhydramine drugs are different, Benidipine belongs to the three kinds of channels can be inhibited by the CCB class of drugs, therefore, not only the peripheral blood vessels have a good effect on the blood pressure.
In addition, in the relief of angina in patients with coronary heart disease, Benidipine has a higher advantage than other depressants, which is mainly from its high affinity for vascular cells and high selectivity for blood vessels, for hypertensive patients with coronary heart disease combined with variant angina pectoris, compared with other depressants, Benidipine is a better choice.
From the name of the drug, we can know that this drug belongs to the sartan class of angiotensin 2 receptor antagonist antihypertensive drugs, but also this drug is China's independent research and development of new drugs in class 1, with a new chemical structure, belonging to the nonpeptide AT1 receptor antagonist class of drugs.
Alisatan ester is a precursor drug, the so-called precursor drug, refers to the drug itself does not have pharmacological activity, but in the body through a certain metabolic combination of the metabolite only after the drug has pharmacological activity. Alisatan ester is metabolized by a large number of esterases present in the gastrointestinal tract and produces an active metabolite, which is able to bind highly selectively to the angiotensin receptor, thus antagonizing the angiotensin-induced increase in blood pressure.
The advantage of this drug is that, although it is a precursor drug, but the drug does not go through the liver metabolism, reducing the impact on the liver and the risk of drug interactions, and can maintain a long-lasting effect on blood pressure control, for mild to moderate hypertension patients, have a very good effect on blood pressure medication, in a 24-hour period of time to take a single dose, you can play a smooth effect of blood pressure medication, the blood pressure peak-to-valley ratio of up to 60% or more.
The active metabolite of ali-sartan ester is the same as the active metabolite of chlorosartan, but its metabolic pathway is simpler, and it will not produce the irrelevant products produced during the metabolism of chlorosartan potassium, therefore, the antihypertensive effect is more clear, and the relative safety of the medication is also higher, and at the same time, this drug for lowering uric acid is also the same as that of chlorosartan potassium, and in the lowering of blood pressure at the same time, it has a certain lowering of uric acid for patients with high uric acid. The drug has the same effect on lowering uric acid as potassium chlorosartan.
Sacubitril valsartan is a new antihypertensive drug with a dual mechanism of action, but it is not a compound preparation, this drug is composed of sacubitril and valsartan in accordance with the molar ratio of 1:1 composition of the dual-active substance **** crystals, therefore, in the classification of the drug, this drug does not belong to the compound preparation, but belongs to the Angiotensin Receptor Enkephalin Peptidase Inhibitor (ARNI) class of drugs. class of drugs.
This drug inhibits the renin-angiotensin-aldosterone system (the role of valsartan) at the same time, the active product of sacubitril in vivo can inhibit the enkephalinase activity, thus promoting the enhancement of the natriuretic peptide system activity, so as to achieve the effect of lowering the blood pressure and protection of the target organ, and the valsartan is exactly to counteract the enhancement of the natriuretic peptide system activity caused by the activation of the RASS, the two drugs The two drugs work synergistically to lower blood pressure and protect target organs such as the heart, kidneys and blood vessels at the same time.
For senile hypertension, refractory hypertension, salt-sensitive hypertension, hypertension combined with heart failure, hypertension combined with left ventricular hypertrophy patients, hypertension combined with chronic kidney disease stage 1 to 3, hypertension combined with obese patients, sakubutra valsartan, are very suitable for the use of antihypertensive drugs, especially in the maintenance treatment of patients with heart failure, sakubutra valsartan instead of sartans or prilosec. Sacubitril valsartan, especially in the maintenance treatment of heart failure patients, replaces sartans or prilosec in antihypertensive drugs, and in combination with other heart failure therapeutic drugs, has obvious advantages in improving the prognosis of heart failure patients and reducing the risk of cardiovascular events.